search
Back to results

Short Course Radiation Therapy in Palliative Treatment of Brain Metastases

Primary Purpose

Brain Metastases, Radiotherapy, Palliative Care

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
standard treatment
short course treatment
Sponsored by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Brain Metastases focused on measuring Short Course Radiotherapy, Symptomatic brain metastases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • symptomatic brain metastases from solid tumors
  • age > 18 years
  • ECOG performance status 0-3
  • no changes in supportive care in the week before radiotherapy

Exclusion Criteria:

  • pregnancy
  • previous irradiation of the same region

Sites / Locations

  • Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

standard treatment

short course treatment

Arm Description

patients in this group are treated with 3000 cGy in 10 daily fractions

patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)

Outcomes

Primary Outcome Measures

Efficacy of palliation using the short course scheme compared with the standard scheme
Reduction of initial symptoms after radiotherapy, assessed with Likert scale (weakness, motor disorders, cognitive impairment, personality changes, loss of balance, seizures, changes in speech, vision, hearing, memory problems, nausea or vomiting are evaluated as none-mild-moderate-severe)

Secondary Outcome Measures

Acute toxicity in the two treatment groups
Incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria
Late toxicity in the two treatment groups
Incidence of treatment-related late adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema
Quality of Life (QoL) assessment in the two groups
Changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)

Full Information

First Posted
May 3, 2018
Last Updated
May 15, 2018
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
search

1. Study Identification

Unique Protocol Identification Number
NCT03525301
Brief Title
Short Course Radiation Therapy in Palliative Treatment of Brain Metastases
Official Title
SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Brain Metastases: an Interventional, Randomised, Multicentric Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Recruiting
Study Start Date
November 8, 2017 (Actual)
Primary Completion Date
November 8, 2022 (Anticipated)
Study Completion Date
November 8, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic brain metastases from solid tumors
Detailed Description
Standard treatment for brain metastases (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (1800 cGy in 4 fractions of 450 cGy twice a day) to demonstrate non-inferiority of this scheme

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Metastases, Radiotherapy, Palliative Care
Keywords
Short Course Radiotherapy, Symptomatic brain metastases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
standard treatment
Arm Type
Active Comparator
Arm Description
patients in this group are treated with 3000 cGy in 10 daily fractions
Arm Title
short course treatment
Arm Type
Experimental
Arm Description
patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
Intervention Type
Radiation
Intervention Name(s)
standard treatment
Intervention Description
3000 cGy in 10 daily fractions
Intervention Type
Radiation
Intervention Name(s)
short course treatment
Intervention Description
1800 cGy in 4 fractions administered twice a day
Primary Outcome Measure Information:
Title
Efficacy of palliation using the short course scheme compared with the standard scheme
Description
Reduction of initial symptoms after radiotherapy, assessed with Likert scale (weakness, motor disorders, cognitive impairment, personality changes, loss of balance, seizures, changes in speech, vision, hearing, memory problems, nausea or vomiting are evaluated as none-mild-moderate-severe)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Acute toxicity in the two treatment groups
Description
Incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria
Time Frame
3 months
Title
Late toxicity in the two treatment groups
Description
Incidence of treatment-related late adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema
Time Frame
12 months
Title
Quality of Life (QoL) assessment in the two groups
Description
Changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: symptomatic brain metastases from solid tumors age > 18 years ECOG performance status 0-3 no changes in supportive care in the week before radiotherapy Exclusion Criteria: pregnancy previous irradiation of the same region
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alessio G Morganti, MD
Phone
0512143564
Ext
+39
Email
alessio.morganti2@unibo.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alessio G Morganti, MD
Organizational Affiliation
Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital
City
Bologna
State/Province
BO
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessio G Morganti, MD
Phone
0512143564
Ext
+39
Email
alessio.morganti2@unibo.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Short Course Radiation Therapy in Palliative Treatment of Brain Metastases

We'll reach out to this number within 24 hrs